|
Market Closed -
Nasdaq
16:00:00 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 6.190 USD | -3.13% |
|
-3.05% | +48.09% |
| 09-21 | Precigen Receives Fda Platform Technology Designation for Adenoverse Platform | CI |
| 09-21 | Precigen's AdenoVerse Receives FDA Platform Technology Designation | MT |
Company Valuation: Precigen, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 767 | 316.4 | 333.6 | 328 | 1,479 | 2,216 | - | - |
| Change | - | -58.75% | 5.42% | -1.66% | 350.89% | 49.85% | - | - |
| Enterprise Value (EV) | 835 | 260.3 | 270.7 | 230.1 | 1,474 | 2,216 | 2,216 | 2,216 |
| Change | - | -68.82% | 3.99% | -15% | 540.71% | 50.32% | 0% | 0% |
| P/E | -7.89x | 10.9x | -3.44x | -2.38x | -3.05x | 27.8x | 9.76x | 8.85x |
| PBR | 7.15x | - | - | - | - | - | - | - |
| PEG | - | -0x | 0x | -0.1x | -0x | -0x | 0x | 0.9x |
| Capitalization / Revenue | 7.38x | 11.8x | 53.6x | 83.6x | 153x | 9.28x | 5x | 4.33x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 9.28x | 5x | 4.33x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | 21.2x | 7.51x | 7.37x |
| EV / FCF | -0x | -0x | -0x | -0x | -0x | 50.6x | 6.37x | 7.75x |
| FCF Yield | -8.22% | -71% | -33.5% | -23.4% | -6.07% | 1.98% | 15.7% | 12.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.47 | 0.14 | -0.39 | -0.47 | -1.37 | 0.2227 | 0.6343 | 0.6997 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 103.9 | 26.91 | 6.225 | 3.925 | 9.684 | 238.8 | 443.5 | 512.1 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -78.78 | -75.73 | -99.76 | -135 | -110.5 | 104.8 | 295.2 | 300.8 |
| Net income 1 | -92.17 | 28.32 | -95.9 | -126.2 | -429.6 | 86.06 | 245.5 | 283.6 |
| Net Debt | 67.99 | -56.07 | -62.86 | -97.91 | -4.684 | - | - | - |
| Reference price 2 | 3.710 | 1.520 | 1.340 | 1.120 | 4.180 | 6.190 | 6.190 | 6.190 |
| Nbr of stocks (in thousands) | 206,738 | 208,150 | 248,919 | 292,869 | 353,824 | 358,035 | - | - |
| Announcement Date | 3/1/22 | 3/6/23 | 3/19/24 | 3/19/25 | 3/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.79x | - | - | - | 2.22B | |
| 37.06x | 13.1x | 27.8x | 0.54% | 1,135B | |
| 38.61x | 6.49x | 18.27x | 2.02% | 635B | |
| 36.46x | 8.38x | 17.29x | 2.41% | 505B | |
| 20.87x | 5.11x | 12.73x | 2.56% | 378B | |
| 105.89x | 5.92x | 25.41x | 2.34% | 358B | |
| 21.76x | 5.68x | 13.94x | 2.81% | 295B | |
| 22.43x | 4.53x | 12.94x | 1.95% | 266B | |
| 27.87x | 7.16x | 12.81x | 2.3% | 237B | |
| -45.48x | 6.98x | 27.06x | 2.11% | 193B | |
| Average | 29.33x | 7.04x | 18.69x | 2.12% | 400.59B | |
| Weighted average by Cap. | 35.22x | 8.29x | 20.39x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PGEN Stock
- Valuation Precigen, Inc.
Select your edition
All financial news and data tailored to specific country editions
